<!DOCTYPE html>
<html lang="en-us">

<head>
  <title>ADHD med shortages push DEA to up drug allotment by 23.5% | Ars Technica</title>
<script type="text/javascript">
  ars = {"ASSETS":"https:\/\/cdn.arstechnica.net\/wp-content\/themes\/ars\/assets","HOME_URL":"https:\/\/arstechnica.com","CIVIS":"\/civis","THEME":"light","VIEW":"grid","MOBILE":false,"SUBSCRIBER":false,"PLUS_PLUS":false,"LOGGED":false,"USER_ID":null,"ENV":"production","AD":{"tags":["adderall","adhd","controlled-substances","dea","drug-shortages","fda","vyvanse"],"channel":"science","slug":"adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage","template_type":"article","queue":[],"server":"production"},"TOTAL":113994,"UNREAD":0,"RECENT":[2047969,2047760,2047904,2047945,2047905,2047906,2047845,2047825,2044077,2047432,2044018,2047423,2046700,2047689,2047690,2047660,2047618,2047606,2047346,2047581,2047492,2047527,2047493,2047501,2047009],"LOGINS":true,"CROSS":false,"PARSELY":"arstechnica.com","COMMENTS":false,"HOMEPAGE":false,"SITE":1,"READY":[],"SHOW_ADS":true,"IMG_PROXY":"https:\/\/cdn.arstechnica.net\/i\/","CATEGORY":"science","PAGETITLE":"","ZEN_MODE":false,"MEMO_PID":"62012a7a19351c07620394e0"};
</script>
<link rel="stylesheet" type="text/css" media="all" href="https://cdn.arstechnica.net/wp-content/themes/ars/assets/css/main-b0320f54e6.css" />
    <link rel="alternate" type="application/rss+xml" href="http://feeds.arstechnica.com/arstechnica/index" />
  <link rel="shortcut icon" href="https://cdn.arstechnica.net/favicon.ico" />
  <link rel="icon" type="image/x-icon" href="https://cdn.arstechnica.net/favicon.ico" />
  <link rel="apple-touch-icon" sizes="180x180" href="https://cdn.arstechnica.net/wp-content/themes/ars/assets/img/ars-ios-icon-d9a45f558c.png" />
  <link rel="mask-icon" href="https://cdn.arstechnica.net/wp-content/themes/ars/assets/img/ars-macos-safari-8997f76b21.svg" color="#ff4e00">
  <link rel="icon" sizes="192x192" href="https://cdn.arstechnica.net/wp-content/themes/ars/assets/img/material-ars-db41652381.png" />
  <link rel="me" href="https://mastodon.social/@arstechnica" />

    <meta name="application-name" content="Ars Technica"/>
  <meta name="msapplication-starturl" content="http://arstechnica.com/"/>
  <meta name="msapplication-tooltip" content="Ars Technica: Serving the technologist for 1.2 decades"/>
  <meta name="msapplication-task" content="name=News;action-uri=http://arstechnica.com/;icon-uri=https://cdn.arstechnica.net/favicon.ico"/>
  <meta name="msapplication-task" content="name=Features;action-uri=http://arstechnica.com/features/;icon-uri=https://cdn.arstechnica.net/ie-jump-menu/jump-features.ico"/>
  <meta name="msapplication-task" content="name=OpenForum;action-uri=http://arstechnica.com/civis/;icon-uri=https://cdn.arstechnica.net/ie-jump-menu/jump-forum.ico"/>
  <meta name="msapplication-task" content="name=Subscribe;action-uri=http://arstechnica.com/subscriptions/;icon-uri=https://cdn.arstechnica.net/ie-jump-menu/jump-subscribe.ico"/>


  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
  <meta name="advertising" content="ask" />
  <meta property="fb:admins" content="592156917" />
  <meta property="fb:admins" content="108943" />
  <meta property="fb:pages" content="19374573752" />

  <meta name="format-detection" content="telephone=no" />
  <meta name="theme-color" content="#000000" />

  
  <meta name="viewport" content="width=device-width,initial-scale=1">

  <!-- cache hit 1:single/meta:b268a94e669be045824d20046d910eab -->
<meta name='parsely-page' content='{"title":"ADHD med shortages push DEA to up drug allotment by 23.5%","link":"https:\/\/arstechnica.com\/science\/2024\/09\/adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage\/","type":"post","author":"Beth Mole","post_id":2047969,"pub_date":"2024-09-06T19:22:21Z","section":"Science","tags":["adderall","adhd","controlled-substances","dea","drug-shortages","fda","vyvanse","type: report"],"image_url":"https:\/\/cdn.arstechnica.net\/wp-content\/uploads\/2024\/09\/GettyImages-1815420320-150x150.jpg"}'>
<meta name='parsely-metadata' content='{"type":"report","title":"ADHD med shortages push DEA to up drug allotment by 23.5%","post_id":2047969,"lower_deck":"The DEA&apos;s quota increase is for Vyvanse and its generic forms.","image_url":"https:\/\/cdn.arstechnica.net\/wp-content\/uploads\/2024\/09\/GettyImages-1815420320-150x150.jpg","listing_image_url":"https:\/\/cdn.arstechnica.net\/wp-content\/uploads\/2024\/09\/GettyImages-1815420320-360x200.jpg"}'>

  <link rel="canonical" href="https://arstechnica.com/science/2024/09/adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage/" />

<link rel="shorturl" href="https://arstechnica.com/?p=2047969" />

<meta name="description" content="The DEA&#39;s quota increase is for Vyvanse and its generic forms." />

<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:url" content="https://arstechnica.com/science/2024/09/adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage/">
<meta name="twitter:title" content="ADHD med shortages push DEA to up drug allotment by 23.5%">
<meta name="twitter:description" content="The DEA&#39;s quota increase is for Vyvanse and its generic forms.">

<meta name="twitter:site" content="@arstechnica">
<meta name="twitter:domain" content="arstechnica.com">

<meta property="og:site_name" content="Ars Technica" />

<meta name="twitter:image:src" content="https://cdn.arstechnica.net/wp-content/uploads/2024/09/GettyImages-1815420320-760x380.jpg">
  <meta name="twitter:image:width" content="760">
  <meta name="twitter:image:height" content="380">

  <meta name="twitter:creator" content="@BethMarieMole">

<meta property="og:url" content="https://arstechnica.com/science/2024/09/adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage/" />
<meta property="og:title" content="ADHD med shortages push DEA to up drug allotment by 23.5%" />
<meta property="og:image" content="https://cdn.arstechnica.net/wp-content/uploads/2024/09/GettyImages-1815420320-760x380.jpg" />
<meta property="og:description" content="The DEA&#39;s quota increase is for Vyvanse and its generic forms." />
<meta property="og:type" content="article" />
  <!-- cache hit 1:single/header:b268a94e669be045824d20046d910eab -->
        

<!-- OneTrust Cookies Consent Notice start -->
<script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" data-domain-script="b10882a1-8446-4e7d-bfb2-ce2c770ad910">
</script>
<script id="oneTrustScripts">
    window.OptanonWrapper = function() {
        var CCPAButton = document.getElementById('ot-sdk-btn');
        CCPAButton && CCPAButton.classList.add('ot-sdk-btn--visible');
        window.dataLayer && window.dataLayer.push({
            event: 'OneTrustGroupsUpdated'
        });
        window.cnBus && window.cnBus.emit('onetrust.OneTrustGroupsUpdated');
    };
</script>
<script src="https://cdn.cookielaw.org/opt-out/otCCPAiab.js" ccpa-opt-out-ids="C0002,C0003,C0004,C0005" ccpa-opt-out-geo="ca" ccpa-opt-out-lspa="true">
</script>
<!-- OneTrust Cookies Consent Notice end -->
<!-- Google Tag Manager DataLayer -->
<script>
window.dataLayer = window.dataLayer || [];
window.dataLayer.push({"event":"data-layer-loaded","user":{"ars_userId":undefined,"amg_userId":undefined,"uID":undefined,"sID":undefined,"loginStatus":false,"subscriberStatus":"none","infinityId":undefined,"registrationSource":undefined,"mdw_cnd_id":undefined,"monthlyVisits":undefined,"accessPaywall":undefined,"view":"grid","theme":"light","show_comments":false},"content":{"pageTemplate":"single","pageType":"article|report","contentCategory":"science","section":"science","subsection":undefined,"contributor":"Beth Mole","contentID":2047969,"contentLength":845,"display":"ADHD med shortages push DEA to up drug allotment by 23.5%","contentSource":"web","pageAssets":undefined,"uniqueContentCount":undefined,"monthlyContentCount":undefined,"publishDate":"2024-09-06T19:22:21-04:00","modifiedDate":"2024-09-06T19:35:11-04:00","keywords":"adderall|ADHD|controlled substances|DEA|drug shortages|fda|Vyvanse","dataSource":undefined},"marketing":{"campaignName":undefined,"circCampaignId":undefined,"internalCampaignId":undefined,"brand":"Ars Technica","certified_mrc_data":undefined,"condeNastId":undefined},"page":{"pID":undefined,"syndicatorUrl":undefined,"pageURL":"https:\/\/arstechnica.com\/?p=2047969","canonical":"https:\/\/arstechnica.com\/science\/2024\/09\/adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage\/","canonicalPathName":"\/science\/2024\/09\/adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage\/"},"search":{"facets":undefined,"searchTerms":undefined},"site":{"appVersion":"1.0.0"}});
</script>
<!-- End Google Tag Manager DataLayer -->
<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-NLXNPCQ');</script>
<!-- End Google Tag Manager -->
<!-- Start Headline A/B -->
<script type="text/javascript">
  class ABTest {
    constructor(post_id, init_method) {
      this.post_id = post_id;
      this.ajaxurl = '/services/ars-ajax-handler.php';
      this.expireDays = 1 / 48; // 30 min
      this.group = this.getGroup();
      this.uid = this.getUid();
      this.init_method = init_method;
      this.setTitle();

      if (this.init_method === 'click') {
        this.click();
      } else {
        this.impression();
      }
    }

    setCookie(name, value, days) {
      var expires = "";
      if (days) {
        var date = new Date();
        date.setTime(date.getTime() + (days * 24 * 60 * 60 * 1000));
        expires = "; expires=" + date.toUTCString();
      }
      document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    getCookie(name) {
      var nameEQ = name + "=";
      var ca = document.cookie.split(';');
      for (var i = 0; i < ca.length; i++) {
        var c = ca[i];
        while (c.charAt(0) == ' ') c = c.substring(1, c.length);
        if (c.indexOf(nameEQ) == 0) return c.substring(nameEQ.length, c.length);
      }
      return null;
    }

    // Retrieves a unique id for determining whether the event should be recorded
    getUid() {
      var uid = this.getCookie('ars_ab_' + this.post_id + '_uid');
      if (!uid) {
        uid = (Math.random() + 1).toString(36).substring(2, 7);
        this.setCookie('ars_ab_' + this.post_id + '_uid', uid, this.expireDays);
      }
      return uid;
    };

    // Places the user in either A or B for this post id
    getGroup() {
      var group = this.getCookie('ars_ab_' + this.post_id + '_group');
      if (!group) {
        group = String.fromCharCode(Math.floor(Math.random() * 2) + 65).toLowerCase();
        this.setCookie('ars_ab_' + this.post_id + '_group', group, this.expireDays);
      }
      return group;
    };

    // Records a headline impression (from homepage or other listing)
    impression() {
      // Send fake ajax
      var params = {
        nonce: 'ef746bfd78',
        action: 'ars_ab_impression',
        id: this.post_id,
        group: this.group,
        uid: this.uid,
        ts: (new Date()).getTime()
      };
      var url = this.ajaxurl + '?' + this.encodeParams(params);
      document.write('\x3Cscript type="text/javascript" src="' + url + '">\x3C/script>');
    };

    // Records a headline click from the actual post page
    click() {
      // Send fake ajax
      var params = {
        nonce: '048061f234',
        action: 'ars_ab_click',
        id: this.post_id,
        group: this.group,
        uid: this.uid,
        ts: (new Date()).getTime()
      };
      var url = this.ajaxurl + '?' + this.encodeParams(params);
      document.write('\x3Cscript type="text/javascript" src="' + url + '">\x3C/script>');
    };

    // If user is in B group, dynamically set title
    setTitle() {
      if (this.group == 'b') {
        var span = document.getElementById('ars_ab_' + this.post_id);
        var title = span.parentNode;
        title.innerHTML = span.getAttribute('data-title-b');
      }
    };

    encodeParams(data) {
      var ret = [];
      for (var d in data)
        ret.push(encodeURIComponent(d) + "=" + encodeURIComponent(data[d]));
      return ret.join("&");
    };

  };
</script>
<!-- End Headline A/B -->
<script>
  window.permutiveCohorts = {"cached_until":{"date":"2024-09-06 23:42:44.947030","timezone_type":3,"timezone":"UTC"},"cohorts":["bjfa","bxwr","bycs"],"gam":["bycs","bjfa","bxwr"],"xandr":[]};
  window.permutiveContextInfo = {"pageProperties":{"client":{"url":"https:\/\/arstechnica.com\/science\/2024\/09\/adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage\/","referrer":"https:\/\/www.netvibes.com\/","type":"web","user_agent":"Mozilla\/5.0 (X11; Fedora; Linux x86_64) AppleWebKit\/537.36 (KHTML, like Gecko) Chrome\/127.0.0.0 Safari\/537.36","domain":"arstechnica.com","title":"ADHD med shortages push DEA to up drug allotment by 23.5% &#8211; Ars Technica"},"type":"article","article":{"id":"2047969","category":"science","subcategory":"","title":"ADHD med shortages push DEA to up drug allotment by 23.5%","tags":["adderall","adhd","controlled-substances","dea","drug-shortages","fda","vyvanse"]}},"url":"https:\/\/arstechnica.com\/science\/2024\/09\/adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage\/"};
</script>
<script src="https://www.googletagservices.com/tag/js/gpt.js" id="gpt-script" async></script>
<script>
  window.googletag = window.googletag || {};
  window.googletag.cmd = window.googletag.cmd || [];
  window.cns = window.cns || {};
  window.cns.queue = [];
  window.cns.async = function(s, c) {
    cns.queue.push({
      service: s,
      callback: c
    })
  };
</script>
<script>
  window.cns.pageContext = {"contentType":"article","templateType":"article","channel":"science","subChannel":"","slug":"adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage","server":"production","keywords":{"tags":["adderall","adhd","controlled-substances","dea","drug-shortages","fda","vyvanse"],"cm":[],"platform":["wordpress"],"copilotid":""}};
</script>
<script src="https://ads-static.conde.digital/production/cns/builds/ars-technica/ars-technica.min.js" async></script>
<script type="text/javascript" src="https://cdn.arstechnica.net/wp-content/themes/ars/assets/js/ars-dc1d08cbd8.ads.us.js"></script>
  <script type="text/javascript">!(function(o,_name){function n(){(n.q=n.q||[]).push(arguments)}n.v=1,o[_name]=o[_name]||n;!(function(o,t,n,c){function e(n){(function(){try{return(localStorage.getItem("v4ac1eiZr0")||"").split(",")[4]>0}catch(o){}return!1})()&&(n=o[t].pubads())&&n.setTargeting("admiral-engaged","true")}(c=o[t]=o[t]||{}).cmd=c.cmd||[],typeof c.pubads===n?e():typeof c.cmd.unshift===n?c.cmd.unshift(e):c.cmd.push(e)})(window,"googletag","function");})(window,String.fromCharCode(97,100,109,105,114,97,108));!(function(t,c,i){i=t.createElement(c),t=t.getElementsByTagName(c)[0],i.async=1,i.src="https://shiverscissors.com/v2fumwIJOo-LsCB0dlG18VSTW43CpWhUEPJuKeRTzrEQdSPPlMr5GymU",t.parentNode.insertBefore(i,t)})(document,"script");</script>

  <!-- Taboola -->
  <script type="text/javascript">
    window._taboola = window._taboola || [];
    _taboola.push({
      article: 'auto'
    });
    ! function(e, f, u, i) {
      if (!document.getElementById(i)) {
        e.async = 1;
        e.src = u;
        e.id = i;
        f.parentNode.insertBefore(e, f);
      }
    }(document.createElement('script'),
      document.getElementsByTagName('script')[0],
      '//cdn.taboola.com/libtrc/condenast1-network/loader.js',
      'tb_loader_script');
    if (window.performance && typeof window.performance.mark == 'function') {
      window.performance.mark('tbl_ic');
    }
  </script>
  <meta name='robots' content='max-image-preview:large' />
<link rel='dns-prefetch' href='//cdn.arstechnica.net' />
<link rel='dns-prefetch' href='//s.w.org' />
<link rel='dns-prefetch' href='//arstechnica-apps.s3.amazonaws.com' />
<link rel='stylesheet' id='wp-block-library-css'  href='https://cdn.arstechnica.net/wp/wp-includes/css/dist/block-library/style.min.css?ver=6.0.3' type='text/css' media='all' />
<style id='global-styles-inline-css' type='text/css'>
body{--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--duotone--dark-grayscale: url('#wp-duotone-dark-grayscale');--wp--preset--duotone--grayscale: url('#wp-duotone-grayscale');--wp--preset--duotone--purple-yellow: url('#wp-duotone-purple-yellow');--wp--preset--duotone--blue-red: url('#wp-duotone-blue-red');--wp--preset--duotone--midnight: url('#wp-duotone-midnight');--wp--preset--duotone--magenta-yellow: url('#wp-duotone-magenta-yellow');--wp--preset--duotone--purple-green: url('#wp-duotone-purple-green');--wp--preset--duotone--blue-orange: url('#wp-duotone-blue-orange');--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;}
</style>
<link rel='stylesheet' id='article_forum_connect_comments-css'  href='https://cdn.arstechnica.net/wp-content/plugins/article-forum-connect/public/css/comments.css?ver=1.2.2' type='text/css' media='all' />
<link rel='stylesheet' id='article_forum_connect_paywall-css'  href='https://cdn.arstechnica.net/wp-content/plugins/article-forum-connect/public/css/paywall.css?ver=1.2.2' type='text/css' media='all' />
<meta property="article:published_time" content="2024-09-06T19:22:21+00:00">
<meta property="article:modified_time" content="2024-09-06T19:35:11+00:00">
<meta name="twitter:partner" content="tfwp" />
<!--
	generated 209 seconds ago
	generated in 0.262 seconds
	served from batcache in 0.002 seconds
	expires in 91 seconds
	billboard: forced 
	view: grid 
	theme: light 
 -->
</head>

<body class="post-template-default single single-post postid-2047969 single-format-standard grid-view light blog-us">
  <!-- Google Tag Manager (noscript) -->
<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-NLXNPCQ" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->

      	<aside class="ad ad_crown" aria-label="Top of page advertisement"></aside>
  
  <div class="site-wrapper">
    <a class="screen-reader-text skip-link" href="#main" aria-label="Skip to main content">Skip to main content</a>
    <header class="site-header">
      <div class="header-left">
        <a href="https://arstechnica.com" id="header-logo" title="Ars Technica Homepage">
      <span class="icon icon-logo-ars-us"></span>
  </a>
      </div>

      <div class="header-right">
        <nav id="header-nav-primary">
          <ul>
            
  <li><a class="nav-link section-information-technology " href="/information-technology/">Biz &amp; IT</a></li>
  <li><a class="nav-link section-gadgets " href="/gadgets/">Tech</a></li>
  <li><a class="nav-link section-science active" href="/science/">Science</a></li>
  <li><a class="nav-link section-tech-policy " href="/tech-policy/">Policy</a></li>
  <li><a class="nav-link section-cars " href="/cars/">Cars</a></li>
  <li><a class="nav-link section-gaming " href="/gaming/">Gaming &amp; Culture</a></li>
  <li><a class="nav-link store" href="/store/">Store</a></li>
  <li><a class="nav-link forums" href="/civis/">Forums</a></li>
          </ul>
        </nav>

                              <a href="/store/product/subscriptions/" class="header-highlight-link">Subscribe</a>
                                  <div class="dropdown" id="header-search">
          <a href="/search/" class="dropdown-toggle search-toggle" aria-label="Search" aria-expanded="false">
            <span class="icon icon-search-mag-glass"></span>
          </a>
          <div class="dropdown-content">
            <form action="/search/" method="GET" id="search_form">
  <input type="hidden" name="ie" value="UTF-8">
  <input type="text" name="q" id="hdr_search_input" value="" aria-label="Search..." placeholder="Search...">
</form>
<a class="nav-search-close">Close</a>
          </div>
        </div>
        <div class="dropdown dropdown-mega" id="header-burger">
          <a href="#site-menu" class="dropdown-toggle" aria-label="Menu" aria-expanded="false">
            <span></span>
          </a>
          <div id="site-menu" class="dropdown-content">
            <section class="burger-navigate">
  <h3>
    <span class="icon icon-half-target"></span>
    Navigate
  </h3>
  <ul>
          <li><a class="nav-link store" href="/store/">Store</a></li>
      <li><a class="nav-link subscribe" href="/store/product/subscriptions/">Subscribe</a></li>
        <li><a class="nav-link videos" href="http://arstechnica.com/video/">Videos</a></li>
    <li><a class="nav-link section-features" href="/features/">Features</a></li>
    <li><a class="nav-link section-reviews" href="/reviews/">Reviews</a></li>
  </ul>

  <ul>
    <li><a class="nav-link page-rss-feeds" href="/rss-feeds/">RSS Feeds</a></li>
    <li><a class="nav-link mobile" href="/?view=mobile">Mobile Site</a></li>
  </ul>

  <ul>
    <li><a class="nav-link page-about-us" href="/about-us/">About Ars</a></li>
    <li><a class="nav-link page-staff-directory" href="/staff-directory/">Staff Directory</a></li>
    <li><a class="nav-link page-contact-us" href="/contact-us/">Contact Us</a></li>
  </ul>

  <ul>
    <li><a class="nav-link page-advertise-with-us" href="https://advertising.condenast.com/brands/ars-technica">Advertise with Ars</a></li>
    <li><a class="nav-link page-reprints" href="/reprints/">Reprints</a></li>
  </ul>
</section>

<section class="burger-filter">
  <h3>
    <span class="icon icon-half-mag"></span>
    Filter by topic
  </h3>
  <ul id="burger-nav-primary">
    
  <li><a class="nav-link section-information-technology " href="/information-technology/">Biz &amp; IT</a></li>
  <li><a class="nav-link section-gadgets " href="/gadgets/">Tech</a></li>
  <li><a class="nav-link section-science active" href="/science/">Science</a></li>
  <li><a class="nav-link section-tech-policy " href="/tech-policy/">Policy</a></li>
  <li><a class="nav-link section-cars " href="/cars/">Cars</a></li>
  <li><a class="nav-link section-gaming " href="/gaming/">Gaming &amp; Culture</a></li>
  <li><a class="nav-link store" href="/store/">Store</a></li>
  <li><a class="nav-link forums" href="/civis/">Forums</a></li>
  </ul>
</section>

<section class="burger-settings">
  <h3>
    <span class="icon icon-half-gear"></span>
    Settings
  </h3>
  <div>
    <div class="burger-layout">
      
<p>Front page layout</p>
<div class="burger-layout-grid">
  <a rel="nofollow" href="/science/2024/09/adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage/?view=grid">
    <span class="icon icon-grid"></span><br>
    Grid
    <div class="faux-radio active"></div>
  </a>
</div>

<div class="burger-layout-list">
  <a rel="nofollow" href="/science/2024/09/adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage/?view=archive">
    <span class="icon icon-list"></span><br>
    List
    <div class="faux-radio "></div>
  </a>
</div>

    </div>
    <div class="burger-theme">
      <p>Site theme</p>
  <div class="burger-theme-light">
    <a rel="nofollow" href="/science/2024/09/adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage/?theme=light">
      <span><span>light</span></span>
      <div class="faux-radio active"></div>
    </a>
  </div>
  <div class="burger-theme-dark">
    <a rel="nofollow" href="/science/2024/09/adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage/?theme=dark">
      <span><span>dark</span></span>
      <div class="faux-radio "></div>
    </a>
  </div>
    </div>
  </div>
</section>
          </div>
        </div>
              <a class="navlink login-link" href="https://arstechnica.com/civis/login?_xfRedirect=%2Fscience%2F2024%2F09%2Fadhd-drug-gets-23-5-production-boost-from-dea-amid-shortage%2F">
      Sign in
    </a>
  
        </div>
    </header>

              
    <main id="main" class="content-wrapper">

<script type="text/javascript">
  ars.ARTICLE = {"url":"https:\/\/arstechnica.com\/science\/2024\/09\/adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage\/","short_url":"https:\/\/arstechnica.com\/?p=2047969","title":"ADHD med shortages push DEA to up drug allotment by 23.5%","author":509873,"authorName":"Beth Mole","pubDate":"2024-09-06T19:22:21Z","id":2047969,"topic":1502792,"pages":1,"current_page":1,"superscroll":true,"promoted":[],"single_page":false,"comments":23,"fullwidth":false,"slug":"adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage","arsStaff":{"104481":{"name":"Aaron Zimmerman","title":"Copy Chief","staff":true},"332715":{"name":"Andrew Cunningham","title":"Senior Technology Reporter","staff":true},"855306":{"name":"Ashley Belanger","title":"Senior Policy Reporter","staff":true},"1002":{"name":"Aurich Lawson","title":"Creative Director","staff":true},"857898":{"name":"Benj Edwards","title":"Senior AI Reporter","staff":true},"509873":{"name":"Beth Mole","title":"Senior Health Reporter","staff":true},"453791":{"name":"Cathleen O'Grady","title":"Contributing science reporter","staff":false},"102179":{"name":"Chris Lee","title":"Associate writer","staff":true},"329388":{"name":"Dan Goodin","title":"Senior Security Editor","staff":true},"254631":{"name":"Diana Gitig","title":"Associate Writer","staff":false},"25862":{"name":"Eric Bangeman","title":"Managing Editor","staff":true},"512413":{"name":"Eric Berger","title":"Senior Space Editor","staff":true},"46707":{"name":"Iljitsch van Beijnum","title":"Associate Writer","staff":false},"316010":{"name":"Jason Marlin","title":"Technical Director","staff":true},"746799":{"name":"Jennifer Ouellette","title":"Senior Writer","staff":true},"15365":{"name":"Jeremy Reimer","title":"Senior Niche Technology Historian","staff":false},"52979":{"name":"John Timmer","title":"Senior Science Editor","staff":true},"312082":{"name":"Jon Brodkin","title":"Senior IT Reporter","staff":true},"14317":{"name":"Jonathan M. Gitlin","title":"Automotive Editor","staff":true},"998":{"name":"Ken Fisher","title":"Editor in Chief","staff":true},"440179":{"name":"Kerry Staurseth","title":"Associate Copyeditor","staff":true},"856780":{"name":"Kevin Purdy","title":"Senior Technology Reporter","staff":true},"328283":{"name":"Kyle Orland","title":"Senior Gaming Editor","staff":true},"10243":{"name":"Lee Hutchinson","title":"Senior Technology Editor","staff":true},"173191":{"name":"Matthew Lasar","title":"Associate writer","staff":true},"182268":{"name":"Nate Anderson","title":"Deputy Editor","staff":true},"1991":{"name":"Ohrmazd","title":"","staff":false},"588289":{"name":"Samuel Axon","title":"Senior Editor","staff":true},"294205":{"name":"Scott K. Johnson","title":"Associate Writer","staff":true},"173910":{"name":"Timothy B. Lee","title":"Senior tech policy reporter","staff":false}},"tags":["adderall","adhd","controlled-substances","dea","drug-shortages","fda","vyvanse"],"zen_mode":false};
</script>

<article itemscope itemtype="http://schema.org/NewsArticle" class="article-single standalone intro-standard " id="">
      <div class="column-wrapper">
    <div class="left-column">
        <header class="article-header">
            <h4 class="post-upperdek">
      drug boost    &mdash;
</h4>
            <h1 itemprop="headline">ADHD med shortages push DEA to up drug allotment by 23.5%</h1>
            <h2 itemprop="description">The DEA's quota increase is for Vyvanse and its generic forms.</h2>
            <section class="post-meta">

  
<p class="byline" itemprop="author creator" itemscope itemtype="http://schema.org/Person">
      <a itemprop="url" href="https://arstechnica.com/author/beth/"  rel="author" ><span itemprop="name">Beth Mole</span></a>
    -    <time class="date" data-time="1725650541" datetime="2024-09-06T19:22:21+00:00">Sep 6, 2024 7:22 pm UTC</time>
</p>

  
</section>        </header>
        <section class="article-guts">
            <div itemprop="articleBody" class="article-content post-page">
                                    
<figure class="intro-image intro-left">
  <img src="https://cdn.arstechnica.net/wp-content/uploads/2024/09/GettyImages-1815420320-800x533.jpg" alt="ADHD med shortages push DEA to up drug allotment by 23.5%">
      <figcaption class="caption"><div class="caption-text"><a href="https://cdn.arstechnica.net/wp-content/uploads/2024/09/GettyImages-1815420320-scaled.jpg" class="enlarge-link" data-height="1707" data-width="2560">Enlarge</a></div><div class="caption-credit"><a rel="nofollow" class="caption-link" href="https://www.gettyimages.com/detail/news-photo/takeda-pharmaceutical-co-vyvanse-brand-lisdexamfetamine-news-photo/1815420320?adppopup=true">Getty | George Frey</a></div></figcaption>  </figure>

  <aside id="social-left" class="social-left" aria-label="Read the comments or share this article">
          <a class="comment-count icon-comment-bubble-down" href="https://arstechnica.com/science/2024/09/adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage/?comments=1">
      <h4 class="comment-count-before">reader comments</h4>
  
  <span class="comment-count-number">23</span>
  </a>
        </aside>




<!-- cache hit 1:single/related:b268a94e669be045824d20046d910eab --><!-- empty -->
<p>While supplies of Adderall and its generic versions are finally recovering after a yearslong shortage, the Drug Enforcement Administration is now working to curb the short supply of another drug for attention-deficit/hyperactivity disorder: Vyvanse (lisdexamfetamine) and its generic versions.</p>
<p>This week, the DEA said it will <a href="https://www.federalregister.gov/documents/2024/09/05/2024-20114/adjustment-to-the-aggregate-production-quota-for-lisdexamfetamine-and-d-amphetamine-for-conversion">increase the allowed production amount of lisdexamfetamine by roughly 23.5 percent</a>, increasing the current 26,500 kg quota by 6,236 kg, for a new total of 32,736 kg. The DEA also allowed for a corresponding increase in d-amphetamine, which is needed for production of lisdexamfetamine.</p>
<p>"These adjustments are necessary to ensure that the United States has an adequate and uninterrupted supply of lisdexamfetamine to meet legitimate patient needs both domestically and globally," the DEA said.</p>
<h2>Quotas</h2>
<p>Just like Adderall (amphetamine/dextroamphetamine salts), Vyvanse (lisdexamfetamine) is an amphetamine-class stimulant classified by the DEA as a <a href="https://www.dea.gov/drug-information/drug-scheduling">Schedule II drug</a>. As such, the DEA controls its production levels to ensure demand is met while preventing excess supply that could find its way to the black market. The administration does this by setting an "aggregate production quota"—which is what the DEA adjusted for lisdexamfetamine this week—and doling out undisclosed allotments to drug manufacturers.</p>
<p>While a variety of factors have contributed to the shortages of ADHD medications, some <a href="https://downloads.aap.org/DOFA/AACAP%20AAP%20CHA%20Joint%20Ltr%20Stimulant%20Shortage%20Final.pdf">medical</a> and industry groups have placed blame on the DEA's quota system for underestimating demand and choking supply. For instance, the Adderall shortage began in 2022 following a labor shortage on the product's production line at Teva, Adderall's maker. But, while that production snag was resolved, prescription rates increased significantly, in part due to increased awareness of ADHD, broadening diagnosis criteria, and an increase in access with the rise of telehealth services, which boomed during the COVID-19 pandemic. In a report earlier this year, the American Society of Health-System Pharmacists pointed to the DEA's quotas, saying they're "<a href="https://www.ashp.org/-/media/assets/drug-shortages/docs/2024/2024-Drug-Shortages-Survey.pdf">exacerbating</a>" shortages.</p>
<p>In <a href="https://www.fda.gov/media/170736/download?attachment">an August 2023 joint letter</a>, the DEA and the FDA responded to such criticism, suggesting that the quotas aren't to blame. Rather, it's that some manufacturers are not using up their allotment of controlled drugs.</p>                                                                        <div class="ars-interlude-container"></div>
                                                                                
<p>"Based on DEA's internal analysis of inventory, manufacturing, and sales data submitted by manufacturers of amphetamine products [which include the two ADHD drugs], manufacturers only sold approximately 70 percent of their allotted quota for the year, and there were approximately 1 billion more doses that they could have produced but did not make or ship. Data for 2023 so far show a similar trend," the FDA and DEA wrote.</p>
<p>The FDA and DEA said they would work with manufacturers to ensure they would ramp up production of drugs in short supply or relinquish their remaining allotments.</p>
<h2>Vyvanse shortage</h2>
<p>A similarly complicated situation is seen with the current shortfall of Vyvanse and its generics. The DEA raised the quota after prodding from the Food and Drug Administration. In July, the FDA sent the DEA a letter requesting a quota increase. But the <a href="https://www.fiercepharma.com/manufacturing/takeda-reports-vyvanse-shortage">shortage had actually begun in June 2023</a>. At that time, Vyvanse's maker, Takeda, said that a "manufacturing delay compounded by increased demand" had led to low inventory.</p>
<p>In August of 2023, the FDA approved <a href="https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-multiple-generics-adhd-and-bed-treatment">multiple generic versions</a> of Vyvanse after Takeda's patent exclusivity expired, raising hopes that the shortage would ease with the injection of new generics. But supply problems have persisted. In November, the Association for Accessible Medicines, which represents generic drug makers, sent a letter to the DEA saying that generic manufacturers weren't able to obtain enough raw material to "launch their products at full commercial scale," because the quotas were standing in the way, <a href="https://www.bloomberg.com/news/articles/2023-11-17/us-limit-on-a-key-adhd-drug-is-worsening-shortages-group-says">according to reporting by Bloomberg</a>.</p>
<p>FiercePharma reported <a href="https://www.fiercepharma.com/pharma/dea-raises-production-limits-takedas-adhd-drug-vyvanse-and-its-generic-versions-shortages">another potential factor</a> raised by lawmakers and industry watchers. Those onlookers took note of the timing of Takeda's "manufacturing delays" just months before generics entered the market. With the significantly thinner profit margin of generic and off-patent drugs, there's concern that manufacturers may de-prioritize production.</p>
<p>Last, the DEA flagged yet another factor in the supply chain: exports to foreign markets. While the FDA estimated a 6 percent increase in the domestic need for lisdexamfetamine between 2023 and 2024, the DEA's export data showed a 34 percent increase in exports of lisdexamfetamine between 2022 and 2023, with expectations that exports would continue to increase this year and beyond. As such, the current 23.5 percent quota increase for lisdexamfetamine is only partly for domestic production. In fact, only a quarter of the 6,236 kg is intended for the US. Of the increased allotment, 1,558 kg is for domestic drug production, while the other 4,678 kg addresses increases in foreign demand, the DEA said.</p>

                                                </div>

            
            
            
        </section>
    </div>
    <div class="xrail">
        <div class="xrail-content">
            
            
            
                                        
            
                            <aside class="ad ad_xrail ad_xrail_top ad_xrail_last" aria-label="Top sidebar advertisement"></aside>
                    </div>
    </div>
</div>

<div class="column-wrapper">
    <div class="left-column">
        <div id="social-footer">
                  <a class="comment-count icon-comment-bubble-down" href="https://arstechnica.com/science/2024/09/adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage/?comments=1">
      <h4 class="comment-count-before">reader comments</h4>
  
  <span class="comment-count-number">23</span>
  </a>
          </div>
                    <!-- cache hit 1:single/author:e25d459d6a94dcd7c0e1f1ef4a380ce3 -->  <section class="article-author">
          <a style="background-image:url('https://cdn.arstechnica.net/wp-content/uploads/2016/05/b.mole-45957.jpg');" class="author-photo" href="/author/beth" tabindex="-1" role="presentation" aria-hidden="true"></a>
    
    <div class="author-bio">
      <section class="author-bio-top">
        <a href="/author/beth" class="author-name">Beth Mole</a>
        Beth is Ars Technica’s Senior Health Reporter. Beth has a Ph.D. in microbiology from the University of North Carolina at Chapel Hill and attended the Science Communication program at the University of California, Santa Cruz. She specializes in covering infectious diseases, public health, and microbes.      </section>
    </div>

  </section>
            </div>
    <div class="xrail"></div>
</div>
<div id="article-footer-wrap">
            <aside class="ad_wrapper" aria-label="Full width advertisement">
    <span class="ad_notice">Advertisement </span>        
    <div class="ad ad_fullwidth fullwidth"></div>
</aside>
    
            <section id="comments-area" class="comments-area column-wrapper">
      <div class="row comments-row left-column">
      <a name="comments-bar"></a>
      
<div class="wp-forum-connect-container">

    

    
</div>

    </div>
          <div class="xrail xrail-comments">
        <div class="xrail-content-wrapper">
          <div class="xrail-content xrail-content-comments">
            <aside class="ad ad_xrail ad_xrail_comments" aria-label="Comments sidebar advertisement"></aside>
          </div>
        </div>
                  <div class="xrail-content-wrapper xrail-content-wrapper-bottom">
            <div class="xrail-content xrail-content-comments">
              <aside class="ad ad_xrail ad_xrail_comments" aria-label="Comments sidebar advertisement"></aside>
            </div>
          </div>
              </div>
      </section>
                    <section class="inline-playlist">
  <div class='ars-video-playlist'>
    <h3 class="ars-video-playlist-module-header">Channel <span>Ars Technica</span></h3>
    <div class='ars-video-playlist-module' data-playlist-id='arstechnica-channel-ars-science' data-video-options='[]'></div>
  </div>
</section>
                <div class="prev-next-links">
  <a href="https://arstechnica.com/space/2024/09/with-nasas-plan-faltering-china-knows-it-can-be-first-with-mars-sample-return/" rel="prev"><span class="arrow">&larr;</span> Previous story</a>  </div>
        <footer id="article-footer">
  <div class="recommendations-footer">
    <div id="story-recommendations">
  <div class="heading-column">
    <h3>Related Stories</h3>
  </div>
  <ul id="story-recs" class="rec-wrap"></ul>
</div>
  </div>
      <div id="taboola-below-article-thumbnails---at"></div>
<script type="text/javascript">
  window._taboola = window._taboola || [];
  _taboola.push({
    mode: 'thumbnails-a-6x1',
    container: 'taboola-below-article-thumbnails---at',
    placement: 'Below Article Thumbnails - AT',
    target_type: 'mix'
  });
</script>
    <div class="recommendations-footer">
    <div id="latest-stories">
  <div class="heading-column">
    <h3>Today on Ars</h3>
  </div>
  <ul id="latest-recs" class="rec-wrap"></ul>
</div>
  </div>
</footer>
    </div>
  </article>
  </main>

  <footer class="site-footer">
    <nav class="nav-footer">

  <section>
    <ul>
      <li><a href="/store/">Store</a></li>
      <li><a href="/store/product/subscriptions/">Subscribe</a></li>
      <li><a href="/about-us/">About Us</a></li>
      <li><a href="/rss-feeds/">RSS Feeds</a></li>
      <li><a rel="nofollow" href="/science/2024/09/adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage/?view=mobile">View Mobile Site</a></li>
    </ul>
  </section>

  <section>
    <ul>
      <li><a href="/contact-us/">Contact Us</a></li>
      <li><a href="/staff-directory/">Staff</a></li>
      <li><a href="https://advertising.condenast.com/brands/ars-technica">Advertise with us</a></li>
      <li><a href="/reprints/">Reprints</a></li>
    </ul>
  </section>

  <section class="footer-newsletter">
    <div class="newsletter-wrapper">
      <h3>
        <a href="/newsletters/" class="footer-newsletter-sign-up">Newsletter Signup</a>
      </h3>
      <p>Join the Ars Orbital Transmission mailing list to get weekly updates delivered to your inbox. <a href="/newsletters/" class="footer-newsletter-sign-up">Sign me up &rarr;</a></p>

      <div class="footer-social-links">
        <a href="https://twitter.com/arstechnica" class="footer-social-twitter">
          <svg style="height: 40px; width: 40px;" id="b" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 40 40">
            <defs>
              <clipPath id="e">
                <rect width="40" height="40" fill="none" />
              </clipPath>
              <clipPath id="f">
                <rect width="40" height="40" fill="none" />
              </clipPath>
            </defs>
            <g id="c">
              <g id="d">
                <g clip-path="url(#e)">
                  <g clip-path="url(#f)">
                    <path d="M16.3,28.1c7.5,0,11.7-6.3,11.7-11.7s0-.4,0-.5c.8-.6,1.5-1.3,2-2.1-.7,.3-1.5,.5-2.4,.6,.9-.5,1.5-1.3,1.8-2.3-.8,.5-1.7,.8-2.6,1-.6-.7-1.4-1.1-2.3-1.2s-1.8,0-2.6,.4c-.8,.4-1.4,1.1-1.8,1.9-.4,.8-.5,1.7-.3,2.6-1.6,0-3.2-.5-4.7-1.2-1.5-.7-2.7-1.8-3.8-3-.5,.9-.7,2-.5,3,.2,1,.9,1.9,1.7,2.5-.7,0-1.3-.2-1.9-.5h0c0,1,.3,1.9,.9,2.7,.6,.7,1.4,1.2,2.4,1.4-.6,.2-1.2,.2-1.9,0,.3,.8,.8,1.5,1.5,2s1.5,.8,2.4,.8c-1.5,1.1-3.2,1.8-5.1,1.8-.3,0-.7,0-1,0,1.9,1.2,4.1,1.8,6.3,1.8" fill="currentColor" />
                  </g>
                </g>
              </g>
            </g>
          </svg>
        </a>
        <a href="https://mastodon.social/@arstechnica" class="footer-social-mastodon">
          <svg style="height: 40px; width: 40px;" id="b" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 40 40">
            <defs>
              <clipPath id="e">
                <rect width="40" height="40" fill="none" />
              </clipPath>
              <clipPath id="f">
                <rect width="40" height="40" fill="none" />
              </clipPath>
            </defs>
            <g id="c">
              <g id="d">
                <g clip-path="url(#e)">
                  <g clip-path="url(#f)">
                    <path d="M29.3,16.6c0-4.3-2.8-5.6-2.8-5.6-1.4-.7-3.9-.9-6.5-1h0c-2.6,0-5,.3-6.4,1,0,0-2.8,1.3-2.8,5.6s0,2.2,0,3.4c.1,4.2,.8,8.4,4.7,9.5,1.8,.5,3.4,.6,4.6,.5,2.3-.1,3.5-.8,3.5-.8v-1.6c0,0-1.7,.5-3.5,.4-1.8,0-3.7-.2-4-2.4,0-.2,0-.4,0-.6,0,0,1.8,.4,4,.5,1.4,0,2.7,0,4-.2,2.5-.3,4.7-1.8,5-3.3,.4-2.2,.4-5.4,.4-5.4h0Zm-3.4,5.6h-2.1v-5.1c0-1.1-.5-1.6-1.4-1.6s-1.5,.6-1.5,1.9v2.8h-2.1v-2.8c0-1.3-.5-1.9-1.5-1.9s-1.4,.5-1.4,1.6v5.1h-2.1v-5.3c0-1.1,.3-1.9,.8-2.6,.6-.6,1.3-1,2.2-1s1.9,.4,2.4,1.2l.5,.9,.5-.9c.5-.8,1.3-1.2,2.4-1.2s1.7,.3,2.2,1c.6,.6,.8,1.5,.8,2.6v5.3Z" fill="currentColor" />
                  </g>
                </g>
              </g>
            </g>
          </svg>
        </a>
        <a href="https://www.facebook.com/arstechnica" class="footer-social-facebook">
          <svg style="height: 40px; width: 40px;" id="b" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 40 40">
            <defs>
              <clipPath id="e">
                <rect width="40" height="40" fill="none" />
              </clipPath>
              <clipPath id="f">
                <rect width="40" height="40" fill="none" />
              </clipPath>
            </defs>
            <g id="c">
              <g id="d">
                <g clip-path="url(#e)">
                  <g clip-path="url(#f)">
                    <path d="M17.3,13.9v2.8h-2v3.4h2v10h4.2v-10h2.8s.3-1.6,.4-3.4h-3.2v-2.3c0-.3,.5-.8,.9-.8h2.3v-3.5h-3.1c-4.4,0-4.3,3.4-4.3,3.9" fill="currentColor" />
                  </g>
                </g>
              </g>
            </g>
          </svg>
        </a>
        <a href="https://www.youtube.com/@arstechnica" class="footer-social-youtube">
          <svg style="height: 40px; width: 40px;" id="b" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 40 40">
            <defs>
              <clipPath id="e">
                <rect width="40" height="40" fill="none" />
              </clipPath>
              <clipPath id="f">
                <rect width="40" height="40" fill="none" />
              </clipPath>
            </defs>
            <g id="c">
              <g id="d">
                <g clip-path="url(#e)">
                  <g clip-path="url(#f)">
                    <path d="M29.6,15.2c-.1-.4-.3-.8-.6-1.1-.3-.3-.7-.5-1.1-.7-1.6-.4-7.8-.4-7.8-.4,0,0-6.3,0-7.8,.4-.4,.1-.8,.3-1.1,.7-.3,.3-.5,.7-.6,1.1-.4,1.6-.4,4.8-.4,4.8,0,0,0,3.3,.4,4.8,.1,.4,.3,.8,.6,1.1,.3,.3,.7,.5,1.1,.7,1.6,.4,7.8,.4,7.8,.4,0,0,6.3,0,7.8-.4,.4-.1,.8-.3,1.1-.7s.5-.7,.6-1.1c.4-1.6,.4-4.8,.4-4.8,0,0,0-3.3-.4-4.8m-11.6,7.8v-5.9l5.2,3-5.2,3Z" fill="currentColor" />
                  </g>
                </g>
              </g>
            </g>
          </svg>
        </a>
        <a href="https://www.instagram.com/arstechnica/" class="footer-social-instagram">
          <svg style="height: 40px; width: 40px;" id="b" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 40 40">
            <defs>
              <clipPath id="e">
                <rect width="40" height="40" fill="none" />
              </clipPath>
              <clipPath id="f">
                <rect width="40" height="40" fill="none" />
              </clipPath>
            </defs>
            <g id="c">
              <g id="d">
                <g clip-path="url(#e)">
                  <g clip-path="url(#f)">
                    <path d="M20,10c2.7,0,3.1,0,4.1,0,1.1,0,1.8,.2,2.4,.5,.7,.3,1.2,.6,1.8,1.2,.6,.6,.9,1.1,1.2,1.8,.2,.6,.4,1.4,.5,2.4,0,1.1,0,1.4,0,4.1s0,3.1,0,4.1c0,1.1-.2,1.8-.5,2.4-.3,.7-.6,1.3-1.2,1.8-.6,.6-1.1,.9-1.8,1.2-.6,.2-1.4,.4-2.4,.5-1.1,0-1.4,0-4.1,0s-3.1,0-4.1,0c-1.1,0-1.8-.2-2.4-.5-.7-.3-1.3-.6-1.8-1.2-.5-.5-.9-1.1-1.2-1.8-.2-.6-.4-1.4-.5-2.4,0-1.1,0-1.4,0-4.1s0-3.1,0-4.1c0-1.1,.2-1.8,.5-2.4,.3-.7,.6-1.2,1.2-1.8,.6-.6,1.1-.9,1.8-1.2,.6-.2,1.4-.4,2.4-.5,1.1,0,1.4,0,4.1,0m0,2.5c-2.4,0-2.7,0-3.7,0-.9,0-1.4,.2-1.7,.3-.4,.1-.8,.4-1.1,.7-.3,.3-.5,.6-.7,1.1-.1,.3-.3,.8-.3,1.7,0,1,0,1.3,0,3.7s0,2.7,0,3.7c0,.9,.2,1.4,.3,1.7,.2,.4,.4,.7,.7,1.1,.3,.3,.6,.5,1.1,.7,.3,.1,.8,.3,1.7,.3,1,0,1.3,0,3.7,0s2.7,0,3.7,0c.9,0,1.4-.2,1.7-.3,.4-.2,.7-.4,1.1-.7,.3-.3,.5-.6,.7-1.1,.1-.3,.3-.8,.3-1.7,0-1,0-1.3,0-3.7s0-2.7,0-3.7c0-.9-.2-1.4-.3-1.7-.1-.4-.4-.8-.7-1.1-.3-.3-.7-.5-1.1-.7-.3-.1-.8-.3-1.7-.3-1,0-1.3,0-3.7,0m0,2.2c.7,0,1.4,.1,2,.4,.6,.3,1.2,.7,1.7,1.1,.5,.5,.9,1.1,1.1,1.7,.3,.6,.4,1.3,.4,2s-.1,1.4-.4,2c-.3,.6-.7,1.2-1.1,1.7-.5,.5-1.1,.9-1.7,1.1-.6,.3-1.3,.4-2,.4-1.4,0-2.7-.6-3.7-1.5-1-1-1.5-2.3-1.5-3.7s.6-2.7,1.5-3.7,2.3-1.5,3.7-1.5m0,8.3c.8,0,1.5-.3,2.1-.9,.6-.6,.9-1.3,.9-2.1s-.3-1.5-.9-2.1c-.6-.6-1.3-.9-2.1-.9s-1.5,.3-2.1,.9c-.6,.6-.9,1.3-.9,2.1s.3,1.5,.9,2.1c.6,.6,1.3,.9,2.1,.9m6.6-8.1c0,.4-.2,.7-.4,1s-.6,.4-1,.4-.7-.2-1-.4c-.3-.3-.4-.6-.4-1s.2-.7,.4-1c.3-.3,.6-.4,1-.4s.7,.2,1,.4c.3,.3,.4,.6,.4,1" fill="currentColor" />
                  </g>
                </g>
              </g>
            </g>
          </svg>
        </a>
      </div>

    </div>
  </section>
</nav>

<section class="footer-terms-logo">
  <div class="cn-logo">
    <a href="http://condenast.com/" class="icon icon-logo-cn-us" title="Visit Condé Nast"></a>
  </div>

  <p id="copyright-terms">
  CNMN Collection<br>
  WIRED Media Group<br>
  © 2024 Condé Nast. All rights reserved. Use of and/or registration on any portion of this site constitutes acceptance of our <a href="https://www.condenast.com/user-agreement/">User Agreement</a> (updated 1/1/20) and <a href="https://www.condenast.com/privacy-policy/">Privacy Policy</a> and <a href="/amendment-to-conde-nast-user-agreement-privacy-policy/">Ars Technica Addendum</a>. Ars may earn compensation on sales from links on this site. <a href="/affiliate-link-policy/">Read our affiliate link policy</a>.<br>
  <span style="display: inline-flex; flex-flow: row nowrap; align-items: center; gap: 5px;"><a href="https://www.condenast.com/privacy-policy/#california">Your California Privacy Rights</a> | <img src="https://cdn.arstechnica.net/wp-content/themes/ars/assets/img/privacyoptions123x59-c5c9972158.png" style="height: 1em; width: auto;" /> <a id="ot-sdk-btn" class="ot-sdk-show-settings">Do Not Sell My Personal Information</a></span><br>
  The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Condé Nast.<br>
  <a href="https://www.aboutads.info/">Ad Choices</a>
</p>
</section>
  </footer>
  </div>

  <script type="text/javascript" src="https://cdn.arstechnica.net/wp-content/themes/ars/assets/js/main-d1ad651ce0.js"></script>


<!-- cache hit 1:single/javascript-footer:b268a94e669be045824d20046d910eab -->
        


    <!-- Taboola -->
  <script type="text/javascript">
    window._taboola = window._taboola || [];
    _taboola.push({
      flush: true
    });
  </script>

  <!-- Parse.ly start -->
<script type="text/plain" class="optanon-category-C0002" id="parsely-cfg" src="//fpa-cdn.arstechnica.com/keys/arstechnica.com/p.js"></script>
<!-- Parse.ly end -->

<!-- Memo start -->
<script type="text/javascript">
__memo_config = {
	pid: ars.MEMO_PID,
	url: ars.ARTICLE.url,
	author: [ars.ARTICLE.authorName],
	title: ars.ARTICLE.title,
	date: ars.ARTICLE.pubDate,
};
(function(){
	var s = document.createElement('script'); 
	s.async = true; 
	s.type = 'text/javascript'; 
	s.src = document.location.protocol + '//cdn.memo.co/js/memo.js';
	(document.getElementsByTagName('head')[0] || document.getElementsByTagName('body') [0]).appendChild(s); 
})();
</script>
<!-- Memo end -->

  
  
    
<script>
  // Load the interlude player.
  window.loadInterludePlayer = function() {
    const src = 'https://player.cnevids.com/interlude/arstechnica.js';

    // Test that script isn't already loaded.
    if (document.querySelector('script[src="' + src + '"]')) {
      return;
    }

    const s = document.createElement('script');
    s.setAttribute('async', true);
    s.setAttribute('src', src);
    document.body.appendChild(s);
  };

  (function() {
    // Only load the interlude player if the container is present.
    if (!document.querySelector('.ars-interlude-container')) {
      return;
    }

    // If sponsored, abort.
    if (document.querySelector('body.single-ars_sponsored_post')) {
      return;
    }

    loadInterludePlayer();
  })();
</script>

<script id="conde-polar" src="https://cdn.mediavoice.com/nativeads/script/condenastcorporate/conde-asa-polar-master.js" async></script>
<script type="text/javascript" src="//s.skimresources.com/js/100098X1555750.skimlinks.js"></script>
<script type='text/javascript' id='snowplow-js-before'>
window.snowplowQueue = window.snowplowQueue || []; window.snowplowContexts = {"site":{"orgId":"4gKgcFGUFUvCGFzHakTPfYp85Yi8","orgAppId":null,"appVersion":null,"env":"production"},"content":{"functionalTags":null,"hasBuyButtons":null,"noOfRevisions":null,"editorNames":null,"author_name":"Beth Mole","contentId":"2047969","contentLength":1,"contentTitle":"ADHD med shortages push DEA to up drug allotment by 23.5%","contentSource":"web","authorIds":"45957","publishDate":"2024-09-06T19:22:21Z","modifiedDate":"2024-09-06T19:35:11Z","tags":"adderall|ADHD|controlled substances|DEA|drug shortages|fda|Vyvanse","contentLang":"en-US","galleryName":null,"totalGalleryImages":null,"wordCount":741,"contentType":null,"templateType":"article_standard_two_column","primaryTag":null,"contentFlag":"news","isCommerceContent":null,"pageTypeProperties":null,"section":"science","subsection":null,"subsection2":null,"dataSource":"web","content_type":"article"},"syndication":{"content":null,"originalSource":null,"originalContentLanguage":null},"page":{"canonical":"https:\/\/arstechnica.com\/science\/2024\/09\/adhd-drug-gets-23-5-production-boost-from-dea-amid-shortage\/","syndicatorUrl":null},"user":{"amguuid":null}}; window.snowplowConfig = {"SNOWPLOW_COLLECTOR":"c.arstechnica.com","SNOWPLOW_SCRIPT":"https:\/\/globalservices.conde.digital\/p77xzrbz9z.js","AVO_API_KEY":"FTJO6mVPBIzdGhjn2Ruy","APP_ID":"ars-technica","APP_NAME":"ars-technica","APP_ENV":"production","APP_VERSION":"1.0.0","COOKIE_DOMAIN":".arstechnica.com"};
</script>
<script type='text/javascript' src='https://cdn.arstechnica.net/wp-content/mu-plugins/ars-snowplow/ars-snowplow-js/dist/main-1-0-4.js?ver=1.0.4' id='snowplow-js'></script>
<script type='text/javascript' src='https://cdn.arstechnica.net/wp-content/plugins/article-forum-connect/public/js/iframeResizer.min.js?ver=1.2.2' id='article_forum_connect_iframe_resizer-js'></script>
<script type='text/javascript' src='https://cdn.arstechnica.net/wp-content/plugins/article-forum-connect/public/js/iframe.js?ver=1.2.2' id='article_forum_connect_iframe-js'></script>
  </body>

  </html>